Shopping Cart 0
Cart Subtotal
AED 0

Global Duloxetine API Market Research Report Forecast to 2023

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 16332

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22938

Details

Duloxetine API Market Information: by Application (Major Depressive Disorder, Generalized Anxiety Disorder (GAD), Fibromyalgia, Neuropathic Pain, Chronic Musculoskeletal Pain), by Region (Americas, Europe, Asia-Pacific, Others)-Forecast till 2023

Market analysis

Active pharmaceutical ingredients (APIs) are utilized in the assembling of pharmaceutical definitions. Duloxetine is a serotonin-norepinephrine reuptake inhibitor utilized in the treatment of discouragement and uneasiness. In addition, it is utilized to help mitigate neuropathic torment in individuals with diabetes or progressing torment because of ailments, for example, joint inflammation, unending back pain, or fibromyalgia. The developing predominance of misery, expanding entrance of conventional medications, expanding instances of nervousness, the developing pattern of outsourcing, strong drug pipeline, and developing interest for recently grown little particle medications are foreseen to support the market development over the forecast time frame. Be that as it may, the components, for example, changing monetary conditions in various areas and symptoms of duloxetine may frustrate the market development over the gauge time frame. The global duloxetine API market is anticipated to register a growth rate of CAGR 3.52% and is expected to reach the value of USD 3,985.0 million by the year 2023.

Market segmentation

The global duloxetine API market has been segmented on the basis of its application and regional demand. Based on its application, the market has been categorized into a generalized anxiety disorder, major depressive disorder, fibromyalgia, chronic musculoskeletal pain, neuropathic pain, and others.

Regional demand

Geographically, the global duloxetine API market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Shodhana Laboratories (India), Hetero (India), Apotex Inc. (Canada), Shionogi Inc. (US), and Zhejiang Huahai Pharmaceutical Co., Ltd (China), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Aurobindo Pharma (India), Lupin (India), Zydus Cadila (India), Eli Lilly and Company (United States), among others are some of the major players in the global duloxetine API market.

READ MORE

Table Of Content

Scope

Table of Contents:

1 Executive Summary

2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.3 Market Structure

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4 Market Dynamics

4.1 Overview

4.2 Drivers

4.2.1 Rising Rates of Anxiety Cases

4.2.2 Increasing Prevalence Rates of Depression

4.2.3 Increasing Penetration of Generic Versions of Drugs

4.2.4 Strong Drug Pipeline

4.2.5 Growing Demand for Newly Developed Small Molecule Drugs

4.2.6 Growing Trend of Outsourcing

4.3 Restraints

4.3.1 Changing Economic Conditions in Different Regions

4.3.2 Side-Effects of Duloxetine

4.4 Opportunities

4.4.1 Advancements in API Manufacturing

4.4.2 Patent Expiry Creating Opportunities for Generic and API Manufacturers

5 Market Factor Analysis

5.1 Supply Chain Analysis

5.1.1 Overview

5.1.2 R&D

5.1.3 Procurement of Raw Material

5.1.4 Manufacturing

5.1.5 Distributor

5.1.6 End User

5.2 Porter's Five Forces Model

5.2.1 Overview

5.2.2 Threat of New Entrants

5.2.3 Bargaining Power of Suppliers

5.2.4 Threat of Substitutes

5.2.5 Bargaining Power of Buyers

5.2.6 Intensity of Rivalry

5.3 Manufacturing Process for API

5.4 Synthesis of Duloxetine Hydrochloride

5.4.1 General Process for Synthesis of Duloxetine Hydrochloride

5.4.2 Variation in the Process According to Different Patents

5.5 Regulatory Scenario

5.5.1 Overview

5.6 Registration of API in the US

5.6.1 US Drug Master File (DMF)

5.7 Registration of API in the European Union (EU)

5.7.1 Active Substance Master File (ASMF)

5.8 Comparison of requirements for the registration of API in the US and the EU

5.9 Registration of Duloxetine API

5.1 Specifications

5.11 Pricing Evolution

5.12 Patent Analysis

5.12.1 Overview

5.12.2 Patent Analysis for Duloxetine Drug

5.13 Patent Analysis for the Preparation of Duloxetine Hydrochloride

5.13.1 Methods for the Preparation of Duloxetine Hydrochloride

5.13.2 Process for the Preparation of Duloxetine Hydrochloride

5.13.3 Method for the Preparation of (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine

Hydrochloride (duloxetine) 35

5.13.4 Process for the Preparation of Duloxetine Hydrochloride

5.13.5 Synthesis and Preparations of Duloxetine Salts

5.13.6 Preparation of Chemically and Enantiomerically Pure Duloxetine HCl

5.13.7 Antidepressant Oral Liquid Compositions

5.14 Duloxetine Hydrochloride Delayed-Release Formulations

5.14.1 Preparation of Duloxetine Hydrochloride Using Optically Active Methylhydroxylaminopropanol Compound as an Intermediate

5.14.2 Process for the Preparation of Duloxetine Hydrochloride

5.14.3 Process for Pure Duloxetine Hydrochloride

5.14.4 Process for the Preparation of Pure Duloxetine Hydrochloride

5.14.5 Process for the Preparation of Duloxetine Hydrochloride and its Precursors

5.15 Product Pipeline Analysis

5.15.1 Overview

5.15.2 Duloxetine (Cymbalta) for Dysthymic Disorder and Depressive Disorder NOS

5.15.3 Effect of Combined Morphine and Duloxetine on Chronic Pain

5.15.4 Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients with Chronic Pain

5.15.5 Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents with Depressive Disorder

5.15.6 Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy

6 Global Duloxetine API Market by Application

6.1 Overview

6.2 Major Depressive Disorder

6.3 Generalized Anxiety Disorder (GAD)

6.4 Fibromyalgia

6.5 Neuropathic Pain

6.6 Chronic Musculoskeletal Pain

6.7 Others

7 Global Duloxetine API Market by Region

7.1 Overview

7.2 Americas

7.2.1 North America

7.2.1.1 US

7.2.1.2 Canada

7.2.2 Latin America

7.3 Europe

7.3.1 Western Europe

7.3.1.1 Germany

7.3.1.2 France

7.3.1.3 UK

7.3.1.4 Italy

7.3.1.5 Spain

7.3.1.6 Rest of Western Europe

7.3.2 Eastern Europe

7.4 Asia-Pacific

7.4.1 China

7.4.2 India

7.4.3 Japan

7.4.4 Rest of Asia-Pacific

7.5 Middle East & Africa

7.5.1 Middle East

7.5.2 Africa

8 Competitive Landscape

8.1 Introduction

8.2 Company Ranking

8.3 Key Customers

9 Company Profiles

9.1 Teva Pharmaceutical Industries Ltd

9.1.1 Company Overview

9.1.2 Financial Overview

9.1.3 Products/Services Offered

9.1.4 Key Developments

9.1.5 SWOT Analysis

9.1.6 Key Strategies

9.2 Sun Pharmaceutical Industries Ltd

9.2.1 Company Overview

9.2.2 Financial Overview

9.2.3 Products/Services Offered

9.2.4 Key Developments

9.2.5 SWOT Analysis

9.2.6 Key Strategies

9.3 Aurobindo Pharma

9.3.1 Company Overview

9.3.2 Financial Overview

9.3.3 Products/Services Offered

9.3.4 Key Developments

9.3.5 SWOT Analysis

9.3.6 Key Strategies

9.4 Lupin

9.4.1 Company Overview

9.4.2 Financial Overview

9.4.3 Products/Services Offered

9.4.4 Key Developments

9.4.5 SWOT Analysis

9.4.6 Key Strategies

9.5 Zydus Cadila

9.5.1 Company Overview

9.5.2 Financial Overview

9.5.3 Products/Services Offered

9.5.4 Key Developments

9.5.5 SWOT Analysis

9.5.6 Key Strategies

9.6 Eli Lilly and Company

9.6.1 Company Overview

9.6.2 Financial Overview

9.6.3 Products Offering

9.6.4 Key Developments

9.6.5 SWOT Analysis

9.6.6 Key Strategies

9.7 Shodhana Laboratories

9.7.1 Company Overview

9.7.2 Financial Overview

9.7.3 Products/Services Offered

9.7.4 Key Developments

9.7.5 SWOT Analysis

9.7.6 Key Strategies

9.8 Hetero

9.8.1 Company Overview

9.8.2 Financial Overview

9.8.3 Products/Services Offered

9.8.4 Key Developments

9.8.5 SWOT Analysis

9.8.6 Key Strategies

9.9 Apotex Inc.

9.9.1 Company Overview

9.9.2 Financial Overview

9.9.3 Products/Services Offered

9.9.4 Key Developments

9.9.5 SWOT Analysis

9.9.6 Key Strategies

9.1 Shionogi Inc.

9.10.1 Company Overview

9.10.2 Financial Overview

9.10.3 Products/Services Offered

9.10.4 Key Developments

9.10.5 SWOT Analysis

9.10.6 Key Strategies

9.11 Zhejiang Huahai Pharmaceutical Co., Ltd

9.11.1 Company Overview

9.11.2 Financial Overview

9.11.3 Products/Services Offered

9.11.4 Key Developments

9.11.5 SWOT Analysis

9.11.6 Key Strategies

10 Appendix

10.1 References

10.2 Related Reports


List Of Figure

List of Figures:

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL DULOXETINE API MARKET: MARKET STRUCTURE

FIGURE 3 RESEARCH PROCESS OF MRFR

FIGURE 4 TOP-DOWN & BOTTOM-UP APPROACH

FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL DULOXETINE API MARKET

FIGURE 6 SUPPLY CHAIN: GLOBAL DULOXETINE API MARKET

FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL DULOXETINE API MARKET

FIGURE 8 GLOBAL DULOXETINE API MARKET, BY APPLICATION, 2017 (%)

FIGURE 9 GLOBAL DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023 (USD MILLION)

FIGURE 10 GLOBAL DULOXETINE API MARKET, BY REGION, 2017 (%)

FIGURE 11 GLOBAL DULOXETINE API MARKET, BY REGION, 2017 AND 2023 (USD MILLION)

FIGURE 12 AMERICAS: DULOXETINE API MARKET, BY REGION, 2017 AND 2023

FIGURE 13 NORTH AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023

FIGURE 14 EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023

FIGURE 15 WESTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023

FIGURE 16 ASIA-PACIFIC: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023

FIGURE 17 MIDDLE EAST & AFRICA: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023


List Of Table

List of Tables:

TABLE 1 DIFFERENCES IN THE API REGISTRATION REQUIREMENTS IN THE US AND EU

TABLE 2 SPECIFICATIONS FOR DULOXETINE

TABLE 3 PRICE RANGE FOR DULOXETINE API (USD/KG)

TABLE 4 PATENT ANALYSIS FOR DULOXETINE DRUG

TABLE 5 DULOXETINE API MARKET: PRODUCT PIPELINE ANALYSIS

TABLE 6 GLOBAL DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 7 GLOBAL DULOXETINE API MARKET FOR MAJOR DEPRESSIVE DISORDER, BY REGION, 2015-2023 (USD MILLION)

TABLE 8 GLOBAL DULOXETINE API MARKET FOR GENERALIZED ANXIETY DISORDER (GAD), BY REGION, 2015-2023 (USD MILLION)

TABLE 9 GLOBAL DULOXETINE API MARKET FOR FIBROMYALGIA, BY REGION, 2015-2023 (USD MILLION)

TABLE 10 GLOBAL DULOXETINE API MARKET FOR NEUROPATHIC PAIN, BY REGION, 2015-2023 (USD MILLION)

TABLE 11 GLOBAL DULOXETINE API MARKET FOR CHRONIC MUSCULOSKELETAL PAIN, BY REGION, 2015-2023 (USD MILLION)

TABLE 12 GLOBAL DULOXETINE API MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 13 GLOBAL DULOXETINE API MARKET VOLUME, BY REGION, 2015-2023 (METRIC TON)

TABLE 14 AMERICAS: DULOXETINE API MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 15 AMERICAS: DULOXETINE API MARKET VOLUME, BY REGION, 2015-2023 (METRIC TON)

TABLE 16 AMERICAS: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 17 NORTH AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 18 NORTH AMERICA: DULOXETINE API MARKET VOLUME, BY COUNTRY, 2015-2023 (METRIC TON)

TABLE 19 NORTH AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 20 US: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 21 CANADA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 22 LATIN AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 23 EUROPE: DULOXETINE API MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 24 EUROPE: DULOXETINE API MARKET VOLUME, BY REGION, 2015-2023 (METRIC TON)

TABLE 25 EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 26 WESTERN EUROPE: DULOXETINE API MARKET, BY COUNTRY, 2015-2023 (USD MILLION)

TABLE 27 WESTERN EUROPE: DULOXETINE API MARKET VOLUME, BY COUNTRY, 2015-2023 (METRIC TON)

TABLE 28 WESTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 29 GERMANY: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 30 FRANCE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 31 UK: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 32 ITALY: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 33 SPAIN: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 34 REST OF WESTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 35 EASTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 36 ASIA-PACIFIC: DULOXETINE API MARKET, BY COUNTRY, 2015-2023 (USD MILLION)

TABLE 37 ASIA-PACIFIC: DULOXETINE API MARKET VOLUME, BY COUNTRY, 2015-2023 (METRIC TON)

TABLE 38 ASIA-PACIFIC: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 39 CHINA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 40 INDIA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 41 JAPAN: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 42 REST OF ASIA-PACIFIC: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA: DULOXETINE API MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA: DULOXETINE API MARKET VOLUME, BY REGION, 2015-2023 (METRIC TON)

TABLE 45 MIDDLE EAST & AFRICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 46 MIDDLE EAST: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 47 AFRICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 48 GLOBAL DULOXETINE API MARKET, RANKING, 2017

TABLE 49 PROMINENT KEY CUSTOMERS FOR DULOXETINE (API)

Licence Rights

"Single User License: OnIine PDF View Only
Enterprise-user License : Print & download option is available."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Shodhana Laboratories (India), Hetero (India), Apotex Inc. (Canada), Shionogi Inc. (US), and Zhejiang Huahai Pharmaceutical Co., Ltd (China), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Aurobindo Pharma (India), Lupin (India), Zydus Cadila (India), Eli Lilly and Company (United States)

Duloxetine API Market Information: by Application (Major Depressive Disorder, Generalized Anxiety Disorder (GAD), Fibromyalgia, Neuropathic Pain, Chronic Musculoskeletal Pain), by Region (Americas, Europe, Asia-Pacific, Others)-Forecast till 2023

Market analysis

Active pharmaceutical ingredients (APIs) are utilized in the assembling of pharmaceutical definitions. Duloxetine is a serotonin-norepinephrine reuptake inhibitor utilized in the treatment of discouragement and uneasiness. In addition, it is utilized to help mitigate neuropathic torment in individuals with diabetes or progressing torment because of ailments, for example, joint inflammation, unending back pain, or fibromyalgia. The developing predominance of misery, expanding entrance of conventional medications, expanding instances of nervousness, the developing pattern of outsourcing, strong drug pipeline, and developing interest for recently grown little particle medications are foreseen to support the market development over the forecast time frame. Be that as it may, the components, for example, changing monetary conditions in various areas and symptoms of duloxetine may frustrate the market development over the gauge time frame. The global duloxetine API market is anticipated to register a growth rate of CAGR 3.52% and is expected to reach the value of USD 3,985.0 million by the year 2023.

Market segmentation

The global duloxetine API market has been segmented on the basis of its application and regional demand. Based on its application, the market has been categorized into a generalized anxiety disorder, major depressive disorder, fibromyalgia, chronic musculoskeletal pain, neuropathic pain, and others.

Regional demand

Geographically, the global duloxetine API market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Shodhana Laboratories (India), Hetero (India), Apotex Inc. (Canada), Shionogi Inc. (US), and Zhejiang Huahai Pharmaceutical Co., Ltd (China), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Aurobindo Pharma (India), Lupin (India), Zydus Cadila (India), Eli Lilly and Company (United States), among others are some of the major players in the global duloxetine API market.

READ MORE

Scope

Table of Contents:

1 Executive Summary

2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.3 Market Structure

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4 Market Dynamics

4.1 Overview

4.2 Drivers

4.2.1 Rising Rates of Anxiety Cases

4.2.2 Increasing Prevalence Rates of Depression

4.2.3 Increasing Penetration of Generic Versions of Drugs

4.2.4 Strong Drug Pipeline

4.2.5 Growing Demand for Newly Developed Small Molecule Drugs

4.2.6 Growing Trend of Outsourcing

4.3 Restraints

4.3.1 Changing Economic Conditions in Different Regions

4.3.2 Side-Effects of Duloxetine

4.4 Opportunities

4.4.1 Advancements in API Manufacturing

4.4.2 Patent Expiry Creating Opportunities for Generic and API Manufacturers

5 Market Factor Analysis

5.1 Supply Chain Analysis

5.1.1 Overview

5.1.2 R&D

5.1.3 Procurement of Raw Material

5.1.4 Manufacturing

5.1.5 Distributor

5.1.6 End User

5.2 Porter's Five Forces Model

5.2.1 Overview

5.2.2 Threat of New Entrants

5.2.3 Bargaining Power of Suppliers

5.2.4 Threat of Substitutes

5.2.5 Bargaining Power of Buyers

5.2.6 Intensity of Rivalry

5.3 Manufacturing Process for API

5.4 Synthesis of Duloxetine Hydrochloride

5.4.1 General Process for Synthesis of Duloxetine Hydrochloride

5.4.2 Variation in the Process According to Different Patents

5.5 Regulatory Scenario

5.5.1 Overview

5.6 Registration of API in the US

5.6.1 US Drug Master File (DMF)

5.7 Registration of API in the European Union (EU)

5.7.1 Active Substance Master File (ASMF)

5.8 Comparison of requirements for the registration of API in the US and the EU

5.9 Registration of Duloxetine API

5.1 Specifications

5.11 Pricing Evolution

5.12 Patent Analysis

5.12.1 Overview

5.12.2 Patent Analysis for Duloxetine Drug

5.13 Patent Analysis for the Preparation of Duloxetine Hydrochloride

5.13.1 Methods for the Preparation of Duloxetine Hydrochloride

5.13.2 Process for the Preparation of Duloxetine Hydrochloride

5.13.3 Method for the Preparation of (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine

Hydrochloride (duloxetine) 35

5.13.4 Process for the Preparation of Duloxetine Hydrochloride

5.13.5 Synthesis and Preparations of Duloxetine Salts

5.13.6 Preparation of Chemically and Enantiomerically Pure Duloxetine HCl

5.13.7 Antidepressant Oral Liquid Compositions

5.14 Duloxetine Hydrochloride Delayed-Release Formulations

5.14.1 Preparation of Duloxetine Hydrochloride Using Optically Active Methylhydroxylaminopropanol Compound as an Intermediate

5.14.2 Process for the Preparation of Duloxetine Hydrochloride

5.14.3 Process for Pure Duloxetine Hydrochloride

5.14.4 Process for the Preparation of Pure Duloxetine Hydrochloride

5.14.5 Process for the Preparation of Duloxetine Hydrochloride and its Precursors

5.15 Product Pipeline Analysis

5.15.1 Overview

5.15.2 Duloxetine (Cymbalta) for Dysthymic Disorder and Depressive Disorder NOS

5.15.3 Effect of Combined Morphine and Duloxetine on Chronic Pain

5.15.4 Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients with Chronic Pain

5.15.5 Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents with Depressive Disorder

5.15.6 Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy

6 Global Duloxetine API Market by Application

6.1 Overview

6.2 Major Depressive Disorder

6.3 Generalized Anxiety Disorder (GAD)

6.4 Fibromyalgia

6.5 Neuropathic Pain

6.6 Chronic Musculoskeletal Pain

6.7 Others

7 Global Duloxetine API Market by Region

7.1 Overview

7.2 Americas

7.2.1 North America

7.2.1.1 US

7.2.1.2 Canada

7.2.2 Latin America

7.3 Europe

7.3.1 Western Europe

7.3.1.1 Germany

7.3.1.2 France

7.3.1.3 UK

7.3.1.4 Italy

7.3.1.5 Spain

7.3.1.6 Rest of Western Europe

7.3.2 Eastern Europe

7.4 Asia-Pacific

7.4.1 China

7.4.2 India

7.4.3 Japan

7.4.4 Rest of Asia-Pacific

7.5 Middle East & Africa

7.5.1 Middle East

7.5.2 Africa

8 Competitive Landscape

8.1 Introduction

8.2 Company Ranking

8.3 Key Customers

9 Company Profiles

9.1 Teva Pharmaceutical Industries Ltd

9.1.1 Company Overview

9.1.2 Financial Overview

9.1.3 Products/Services Offered

9.1.4 Key Developments

9.1.5 SWOT Analysis

9.1.6 Key Strategies

9.2 Sun Pharmaceutical Industries Ltd

9.2.1 Company Overview

9.2.2 Financial Overview

9.2.3 Products/Services Offered

9.2.4 Key Developments

9.2.5 SWOT Analysis

9.2.6 Key Strategies

9.3 Aurobindo Pharma

9.3.1 Company Overview

9.3.2 Financial Overview

9.3.3 Products/Services Offered

9.3.4 Key Developments

9.3.5 SWOT Analysis

9.3.6 Key Strategies

9.4 Lupin

9.4.1 Company Overview

9.4.2 Financial Overview

9.4.3 Products/Services Offered

9.4.4 Key Developments

9.4.5 SWOT Analysis

9.4.6 Key Strategies

9.5 Zydus Cadila

9.5.1 Company Overview

9.5.2 Financial Overview

9.5.3 Products/Services Offered

9.5.4 Key Developments

9.5.5 SWOT Analysis

9.5.6 Key Strategies

9.6 Eli Lilly and Company

9.6.1 Company Overview

9.6.2 Financial Overview

9.6.3 Products Offering

9.6.4 Key Developments

9.6.5 SWOT Analysis

9.6.6 Key Strategies

9.7 Shodhana Laboratories

9.7.1 Company Overview

9.7.2 Financial Overview

9.7.3 Products/Services Offered

9.7.4 Key Developments

9.7.5 SWOT Analysis

9.7.6 Key Strategies

9.8 Hetero

9.8.1 Company Overview

9.8.2 Financial Overview

9.8.3 Products/Services Offered

9.8.4 Key Developments

9.8.5 SWOT Analysis

9.8.6 Key Strategies

9.9 Apotex Inc.

9.9.1 Company Overview

9.9.2 Financial Overview

9.9.3 Products/Services Offered

9.9.4 Key Developments

9.9.5 SWOT Analysis

9.9.6 Key Strategies

9.1 Shionogi Inc.

9.10.1 Company Overview

9.10.2 Financial Overview

9.10.3 Products/Services Offered

9.10.4 Key Developments

9.10.5 SWOT Analysis

9.10.6 Key Strategies

9.11 Zhejiang Huahai Pharmaceutical Co., Ltd

9.11.1 Company Overview

9.11.2 Financial Overview

9.11.3 Products/Services Offered

9.11.4 Key Developments

9.11.5 SWOT Analysis

9.11.6 Key Strategies

10 Appendix

10.1 References

10.2 Related Reports


List Of Figure

List of Figures:

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL DULOXETINE API MARKET: MARKET STRUCTURE

FIGURE 3 RESEARCH PROCESS OF MRFR

FIGURE 4 TOP-DOWN & BOTTOM-UP APPROACH

FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL DULOXETINE API MARKET

FIGURE 6 SUPPLY CHAIN: GLOBAL DULOXETINE API MARKET

FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL DULOXETINE API MARKET

FIGURE 8 GLOBAL DULOXETINE API MARKET, BY APPLICATION, 2017 (%)

FIGURE 9 GLOBAL DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023 (USD MILLION)

FIGURE 10 GLOBAL DULOXETINE API MARKET, BY REGION, 2017 (%)

FIGURE 11 GLOBAL DULOXETINE API MARKET, BY REGION, 2017 AND 2023 (USD MILLION)

FIGURE 12 AMERICAS: DULOXETINE API MARKET, BY REGION, 2017 AND 2023

FIGURE 13 NORTH AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023

FIGURE 14 EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023

FIGURE 15 WESTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023

FIGURE 16 ASIA-PACIFIC: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023

FIGURE 17 MIDDLE EAST & AFRICA: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023


List Of Table

List of Tables:

TABLE 1 DIFFERENCES IN THE API REGISTRATION REQUIREMENTS IN THE US AND EU

TABLE 2 SPECIFICATIONS FOR DULOXETINE

TABLE 3 PRICE RANGE FOR DULOXETINE API (USD/KG)

TABLE 4 PATENT ANALYSIS FOR DULOXETINE DRUG

TABLE 5 DULOXETINE API MARKET: PRODUCT PIPELINE ANALYSIS

TABLE 6 GLOBAL DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 7 GLOBAL DULOXETINE API MARKET FOR MAJOR DEPRESSIVE DISORDER, BY REGION, 2015-2023 (USD MILLION)

TABLE 8 GLOBAL DULOXETINE API MARKET FOR GENERALIZED ANXIETY DISORDER (GAD), BY REGION, 2015-2023 (USD MILLION)

TABLE 9 GLOBAL DULOXETINE API MARKET FOR FIBROMYALGIA, BY REGION, 2015-2023 (USD MILLION)

TABLE 10 GLOBAL DULOXETINE API MARKET FOR NEUROPATHIC PAIN, BY REGION, 2015-2023 (USD MILLION)

TABLE 11 GLOBAL DULOXETINE API MARKET FOR CHRONIC MUSCULOSKELETAL PAIN, BY REGION, 2015-2023 (USD MILLION)

TABLE 12 GLOBAL DULOXETINE API MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 13 GLOBAL DULOXETINE API MARKET VOLUME, BY REGION, 2015-2023 (METRIC TON)

TABLE 14 AMERICAS: DULOXETINE API MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 15 AMERICAS: DULOXETINE API MARKET VOLUME, BY REGION, 2015-2023 (METRIC TON)

TABLE 16 AMERICAS: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 17 NORTH AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 18 NORTH AMERICA: DULOXETINE API MARKET VOLUME, BY COUNTRY, 2015-2023 (METRIC TON)

TABLE 19 NORTH AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 20 US: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 21 CANADA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 22 LATIN AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 23 EUROPE: DULOXETINE API MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 24 EUROPE: DULOXETINE API MARKET VOLUME, BY REGION, 2015-2023 (METRIC TON)

TABLE 25 EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 26 WESTERN EUROPE: DULOXETINE API MARKET, BY COUNTRY, 2015-2023 (USD MILLION)

TABLE 27 WESTERN EUROPE: DULOXETINE API MARKET VOLUME, BY COUNTRY, 2015-2023 (METRIC TON)

TABLE 28 WESTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 29 GERMANY: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 30 FRANCE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 31 UK: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 32 ITALY: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 33 SPAIN: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 34 REST OF WESTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 35 EASTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 36 ASIA-PACIFIC: DULOXETINE API MARKET, BY COUNTRY, 2015-2023 (USD MILLION)

TABLE 37 ASIA-PACIFIC: DULOXETINE API MARKET VOLUME, BY COUNTRY, 2015-2023 (METRIC TON)

TABLE 38 ASIA-PACIFIC: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 39 CHINA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 40 INDIA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 41 JAPAN: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 42 REST OF ASIA-PACIFIC: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA: DULOXETINE API MARKET, BY REGION, 2015-2023 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA: DULOXETINE API MARKET VOLUME, BY REGION, 2015-2023 (METRIC TON)

TABLE 45 MIDDLE EAST & AFRICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 46 MIDDLE EAST: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 47 AFRICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)

TABLE 48 GLOBAL DULOXETINE API MARKET, RANKING, 2017

TABLE 49 PROMINENT KEY CUSTOMERS FOR DULOXETINE (API)

"Single User License: OnIine PDF View Only
Enterprise-user License : Print & download option is available."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Shodhana Laboratories (India), Hetero (India), Apotex Inc. (Canada), Shionogi Inc. (US), and Zhejiang Huahai Pharmaceutical Co., Ltd (China), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Aurobindo Pharma (India), Lupin (India), Zydus Cadila (India), Eli Lilly and Company (United States)